studies

breast cancer - HR positive, IGF-1R inhibitors vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsQUILT-2.015, 2013 1.78 [1.27; 2.50] 1.78[1.27; 2.50]QUILT-2.015, 201310%NAnot evaluable progression or deaths (PFS)detailed resultsMK-8669-064, 2017 1.18 [0.81; 1.72] QUILT-2.015, 2013 1.17 [0.91; 1.50] 1.17[0.95; 1.44]MK-8669-064, 2017, QUILT-2.015, 201320%236lownot evaluable objective responses (ORR)detailed resultsMK-8669-064, 2017 0.53 [0.17; 1.63] QUILT-2.015, 2013 0.60 [0.15; 2.42] 0.56[0.23; 1.34]MK-8669-064, 2017, QUILT-2.015, 201320%175moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-12 08:21 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 4,319,144,356,351,357,352,354,353,358,359 - treatments: 1427,1441,1428

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons